-

Summit Therapeutics to Host Corporate Update and Operational Progress Call on November 30, 2026

Conference Call to Be Held at 8:00 a.m. EST

MIAMI--(BUSINESS WIRE)--Summit Therapeutics Inc. (Nasdaq: SMMT) will host a corporate update and operational progress conference call and webcast on Monday, November 30, 2026. The call is scheduled to take place at 8:00 a.m. EST.

The conference call and webcast details, including dial-in information and webcast link, will be posted on the Investor Relations section of Summit's website, www.smmttx.com. The archived webcast will be available through the company's website after the call has concluded.

About Summit Therapeutics

Summit Therapeutics Inc. is a biopharmaceutical oncology company focused on the discovery, development, and commercialization of patient-, physician-, caregiver- and societal-friendly medicinal therapies intended to improve quality of life, increase potential duration of life, and resolve serious unmet medical needs.

Summit was founded in 2003 and its shares are listed on the Nasdaq Global Market (symbol "SMMT"). The company is headquartered in Miami, Florida, with additional offices in Palo Alto, California, Princeton, New Jersey, Dublin, Ireland, and Oxford, UK.

For more information, please visit https://www.smmttx.com and follow us on X @SMMT_TX.

Summit Forward-looking Statements

Any statements in this press release about the Company’s future expectations, plans and prospects, including but not limited to, statements about the clinical and preclinical development of the Company’s product candidates, entry into and actions related to the Company’s partnership with Akeso Inc. and other collaborations, the Company's anticipated spending and cash runway, the therapeutic potential of the Company’s product candidates, the potential commercialization of the Company’s product candidates, the timing of initiation, completion and availability of data from clinical trials, the potential submission of applications for marketing approvals, the expected timing of BLA submissions or FDA decisions, potential acquisitions, statements about the previously disclosed At-The-Market equity offering program (“ATM Program”), or the AstraZeneca private placement, the expected proceeds, uses thereof and possibility that the proceeds will not be sufficient to fund operations as long as anticipated, dilution to existing stockholders and potential adverse effects on the market price of the Company’s common stock, including from future sales by AstraZeneca, AstraZeneca’s ownership and contractual rights, including Third Party acquisition participation, registration rights and potential conflicts of interest, the Company’s reliance on third parties for the supply of third party products and other contributions to certain combination clinical trials, the Company’s estimates regarding stock-based compensation, and other statements containing the words "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project," "should," "target," "would," and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including the Company’s ability to sell shares of our common stock under the ATM Program, the conditions affecting the capital markets, general economic, market, industry, or political conditions, including the effects of geopolitical developments, domestic and foreign trade policies, and monetary policies, the results of our evaluation of the underlying data in connection with the development and commercialization activities for ivonescimab, the outcome of discussions with regulatory authorities, including the Food and Drug Administration, the uncertainties inherent in the initiation of future clinical trials, availability and timing of data from ongoing and future clinical trials, the results of such trials, and their success, global public health crises, that may affect timing and status of our clinical trials and operations, whether preliminary results from a clinical trial will be predictive of the final results of that trial or whether results of early clinical trials or preclinical studies will be indicative of the results of later clinical trials, whether business development opportunities to expand the Company’s pipeline of drug candidates, including without limitation, through potential acquisitions of, and/or collaborations with, other entities occur, expectations for regulatory approvals, laws and regulations affecting government contracts and funding awards, availability of funding sufficient for the Company’s foreseeable and unforeseeable operating expenses and capital expenditure requirements and other factors discussed in the "Risk Factors" and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections of filings that the Company makes with the Securities and Exchange Commission. Summit defines a “positive study” as a clinical study with one or more prespecified primary endpoints in which one of those endpoints achieves a statistically significant benefit according to the protocol or statistical analysis plan. Any change to our ongoing trials could cause delays, affect our future expenses, and add uncertainty to our commercialization efforts, as well as to affect the likelihood of the successful completion of clinical development of ivonescimab. Accordingly, readers should not place undue reliance on forward-looking statements or information. In addition, any forward-looking statements included in this press release represent the Company’s views only as of the date of this release and should not be relied upon as representing the Company’s views as of any subsequent date. The Company specifically disclaims any obligation to update any forward-looking statements included in this press release.

Summit Therapeutics and the Summit Therapeutics logo are registered trademarks of Summit Therapeutics Inc. and/or its affiliates. Copyright 2026, Summit Therapeutics Inc. All Rights Reserved.

Contacts

Contact Summit Investor Relations:
Nathan LiaBraaten
Senior Director, Investor Relations

Tracy Jones
Director, Media & Public Relations

investors@smmttx.com
media@smmttx.com

Summit Therapeutics

NASDAQ:SMMT

Release Versions
$Cashtags

Contacts

Contact Summit Investor Relations:
Nathan LiaBraaten
Senior Director, Investor Relations

Tracy Jones
Director, Media & Public Relations

investors@smmttx.com
media@smmttx.com

Social Media Profiles
More News From Summit Therapeutics

Summit Therapeutics Further Expands Ivonescimab Global Development Program with Phase III HARMONi-10 Study in Unresectable Stage III Non-Small Cell Lung Cancer

MIAMI--(BUSINESS WIRE)--Summit Therapeutics Inc. (NASDAQ: SMMT) today announced the initiation of a new global Phase III clinical trial of ivonescimab, an investigational, novel PD-1 x VEGF bispecific antibody, in non-small cell lung cancer (NSCLC). The study, HARMONi-10, will evaluate ivonescimab compared with durvalumab as consolidation therapy in patients with locally advanced, unresectable Stage III NSCLC who have not experienced disease progression following platinum-based concurrent chemo...

Summit Therapeutics Provides Update Regarding Ivonescimab Biologics License Application

MIAMI--(BUSINESS WIRE)--Summit Therapeutics Inc. (NASDAQ: SMMT) today announced that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) regarding the Biologics License Application (BLA) for ivonescimab in combination with platinum-containing chemotherapy for the treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC), who have received prior epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) therapy....

Summit Therapeutics Reports Financial Results and Operational Progress for the Third Quarter and Nine Months Ended September 30, 2026

MIAMI--(BUSINESS WIRE)--Summit Therapeutics Inc. (NASDAQ: SMMT) today reported its financial results for the third quarter and nine months ended September 30, 2026, and provided an update on clinical and operational progress. “This quarter marked a period of meaningful momentum for Summit, highlighted by AstraZeneca’s $2 billion strategic equity investment and the expansion of our network of clinical collaborations with AstraZeneca, Daiichi Sankyo, and several others,” said Robert W. Duggan, Ch...
Back to Newsroom